Dewpoint Therapeutics
Kip West is an accomplished professional in the field of pharmacology and oncology, currently serving as the Head of Translational Pharmacology at Dewpoint Therapeutics since January 2023. Prior to this role, Kip held significant positions including Executive Director and Head of Experimental Biology at Boston Pharmaceuticals from May 2021 to January 2023, and Director of In Vivo Pharmacology at Akebia Therapeutics from July 2019 to May 2021. Previous experience includes leadership roles at Synlogic, Inc. as Director of Immunomodulation and Director of Pharmacology, and as Associate Director of Biological Sciences at Epizyme, where contributions focused on developing novel small molecule histone methyltransferase inhibitors for personalized cancer therapeutics. Kip West earned a PhD in Cell and Molecular Biology from Upstate Medical University and a BS in Biology from the University of Wisconsin-Madison.
This person is not in any teams
This person is not in any offices
Dewpoint Therapeutics
Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions has pathways that are regulated by condensates or arise from the dysfunction of condensates - including cancer, neurodegeneration, and metabolic disease.